Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cel... ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term immunological memory. Mehr anzeigen
Confirmatory trial builds on results of QUILT 3.055, a Phase 2 trial demonstrating ANKTIVA rescued T cells and activity of checkpoint inhibitors (CPIs) in patients with non-small cell lung...
Application covers 30 countries in the European Union Submission is based on the ongoing QUILT 3.032 study in which 100 patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle...
BCG unresponsive non-muscle invasive bladder cancer (NMIBC) in the papillary indication: Anticipated supplemental biologics license application (BLA) submission in 2025 Alternative source of BCG...
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code assigned by the Centers for...
CULVER CITY, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the pricing of its previously announced underwritten...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.08 | 2.5974025974 | 3.08 | 3.72 | 2.91 | 7590998 | 3.14514124 | CS |
| 4 | 0.58 | 22.480620155 | 2.58 | 3.72 | 2.28 | 6990607 | 2.89203483 | CS |
| 12 | -2.23 | -41.3729128015 | 5.39 | 5.88 | 2.28 | 6083742 | 3.49715947 | CS |
| 26 | -2.24 | -41.4814814815 | 5.4 | 7.48 | 2.28 | 5293809 | 4.05978777 | CS |
| 52 | -0.5 | -13.6612021858 | 3.66 | 10.53 | 2.28 | 5321506 | 5.23877989 | CS |
| 156 | -2.28 | -41.9117647059 | 5.44 | 10.53 | 1.21 | 3789564 | 4.27809265 | CS |
| 260 | -33.39 | -91.3543091655 | 36.55 | 40.834 | 1.21 | 3205098 | 5.0138714 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
